Mizolastine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Identifiers
  • 2-[{1-[1-(4-Fluorobenzyl)-1H-benzimidazol-2-yl]piperidin-4-yl}(methyl)amino]pyrimidin-4(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.149.406
Chemical and physical data
FormulaC24H25FN6O
Molar mass432.503 g·mol−1
3D model (JSmol)
  • CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
  • InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32) ☒N
  • Key:PVLJETXTTWAYEW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Mizolastine (Mizollen) is a once-daily, non-sedating antihistamine. It blocks H1 receptors and is commonly fast-acting.[1] It does not prevent the actual release of histamine from mast cells, it only prevents histamine from binding to receptors. Side effects can include dry mouth and throat.[2]

References

  1. ↑ Simons FE (March 1999). "Mizolastine: antihistaminic activity from preclinical data to clinical evaluation". Clinical and Experimental Allergy. 29 (Suppl 1): 3–8. doi:10.1046/j.1365-2222.1999.00002.x. PMID 10209699. S2CID 616333.
  2. ↑ "MIZOLASTINE: British National Formulary". Retrieved 2010-02-01.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.